Bristol-Myers Squibb stock slips 1.73 percent on September 23

Bristol-Myers Squibb stock (NYSE: BMY) fell 1.73 percent to USD 61.17 in trading on September 23, 2026. The move leaves the shares 10.88 percent below their 52-week high of USD 68.64, while the company enters the next reporting cycle after a stronger second quarter.

Second-quarter revenue reached USD 12.973 billion

Bristol Myers Squibb reported Q2 2026 revenue of USD 12.9 billion, up 6 percent from the same quarter a year earlier, according to The Motley Fool on September 20, 2026. That growth gives the stock a concrete operating reference as investors assess the pharmaceutical company's earnings path.

Q2 diluted EPS reached USD 1.62, a 153 percent increase from the year-earlier quarter, the same report said. The combination of 6 percent revenue growth and triple-digit EPS growth reflects a much stronger earnings comparison than the top-line change alone suggests.

Goldman Sachs keeps a Neutral view

Goldman Sachs reiterated its Neutral rating and USD 63.00 price target on September 23, 2026, according to Investing.com. The target sits USD 1.83 above the intraday quote, leaving the analyst view close to the current market level rather than signaling a wide valuation gap.

The market capitalization stood at USD 124,962,782,692 on September 23, 2026. The stock's 52-week range was USD 42.52 to USD 68.64, placing the current quote materially above the yearly low but below the upper end of that span.

Third-quarter date is set

Bristol Myers Squibb plans to report third-quarter 2026 results on October 29, 2026, with an earnings call scheduled for 8:00 a.m. ET, according to Yahoo Finance in a release dated September 18, 2026. That date provides the next defined checkpoint for revenue trends, EPS comparisons and management commentary.

Stock trades below its yearly high

At USD 61.17 on the NYSE on September 23, 2026, Bristol-Myers Squibb stock remained 10.88 percent below its 52-week high of USD 68.64. The combination of the daily decline, Q2 growth figures and the Neutral rating gives the shares a measurable set of market and earnings reference points.